You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

19 search results for: neuroimmune mechanisms

<b>Neuroimmune</b> Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
<b>Neuroimmune</b> Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Mast Cells and the <b>Neuroimmune</b> Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Itch: <b>Neuroimmune</b> Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
A Triad of Interacting <b>Mechanisms</b> Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Type 2 Inflammation
Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases
View more
Skin Barrier, <b>Neuroimmune</b> Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Dermatology
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
View more
ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases
Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

Type 2 Inflammation
Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care
View more
ADVENT On Air | Loss of Smell in CRSwNP Patients
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

Rhinology
Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.
View more
ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Dermatology
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Hong KongChange country/region